Immunome, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Bothell, wash.--(business wire)--immunome, inc. (nasdaq: imnm), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for im-3050, the company's lead lutetium-177 radioligand therapy (rlt) targeting fibroblast activation protein (fap). jack higgins, phd, chief scientific officer at immunome, will present the data in a poster at the american association for cancer research (aacr) annual meet.

Bothell, wash.--(business wire)--immunome, inc. (nasdaq: imnm), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended december 31, 2023, and provided an overview of recent developments. “2023 was a transformative year for immunome as we closed the merger with morphimmune, advanced our pipeline and expanded the company's leadership team,” said clay b. siegall, ph.d., president and chief.

Bothell, wash.--(business wire)--immunome, inc. (nasdaq: imnm), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of al102 and related drug candidate al101 from ayala pharmaceuticals, inc. “al102 is a high-quality asset that complements our existing pipeline of targeted cancer therapies,” said clay b. siegall, ph.d., president and chief executive officer of immunome. “we believe tha.

Edinburgh, scotland--(business wire)--arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its arrayplex™ discovery platform has been selected by immunome, inc. (nasdaq: imnm), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools. the proprietary multi-layer microarray platform is also available to arrayjet's screening customers through its cro/cmo serv.

Bothell, wash.--(business wire)--immunome, inc. (nasdaq: imnm), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that clay siegall, ph.d., president and ceo of immunome, will present at the leerink partners 2024 global biopharma conference on tuesday, march 12, 2024 at 4:20 p.m. et. interested parties can access the live audio webcast for this conference from the investor relations section of the company's website at www.i.

IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.

IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25. IMNM is also looking to acquire some antibody-related assets and materials from Atreca, subject to a stockholder vote.

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com.

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new CEO of IMNM. Siegall co-founded and led Seagen for over 20 years. Immunome intends to raise $125M via a PIPE, which is oversubscribed, providing the company with sufficient funds to develop the potential merged pipeline.

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.

Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development. Even if IMNM can't find a partner for IMM-BCP-01, a new collaboration agreement with ABBV is arguably a more exciting development.